Alluri Ravindra V, Li Rui, Varma Manthena V S
Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK.
Modeling and Simulations, Medicine Design, Worldwide Research and Development, Pfizer Inc., Cambridge, MA, USA.
Expert Opin Drug Metab Toxicol. 2020 May;16(5):387-401. doi: 10.1080/17425255.2020.1749595. Epub 2020 Apr 12.
: Transporters and enzymes play an important role in absorption, distribution, clearance and elimination of drugs.: This review provides an overview of the extended clearance concept and usefulness of extended clearance classification system (ECCS) in early identification of predominant clearance mechanisms. Clinical studies demonstrating transporter-enzyme interplay, challenges in scaling clearance from in vitro systems, utility of animal models and modeling approaches for evaluating hepatic clearance and drug-drug interactions are reviewed.: Clinical evidence exists supporting organic anion transporting peptide (OATP)1B and drug metabolizing enzymes involvement in clearance of ECCS class 1B drugs. Emerging evidence point toward contribution of organic cation transporter (OCT)1 to hepatic uptake of cationic drugs. Although, limited clinical evidence is presented, preclinical studies and modeling suggests organic anion transporter (OAT)2-enzyme interplay in clearance of class 1A drugs. Data from assays and preclinical models coupled with physiologically based modeling approaches are key for understanding transporter-enzyme interplay, enabling prediction of pharmacokinetics, tissue exposure and drug interactions. Current methodologies incur limitations and emphasis should be placed on the development of physiologically relevant models and characterize animal models to inform mechanistic modeling and improve confidence in prospective predictions.
转运体和酶在药物的吸收、分布、清除和排泄过程中发挥着重要作用。本综述概述了扩展清除概念以及扩展清除分类系统(ECCS)在早期识别主要清除机制方面的实用性。对证明转运体 - 酶相互作用的临床研究、从体外系统推算清除率的挑战、动物模型的效用以及评估肝清除率和药物 - 药物相互作用的建模方法进行了综述。有临床证据支持有机阴离子转运多肽(OATP)1B和药物代谢酶参与ECCS 1B类药物的清除。新出现的证据表明有机阳离子转运体(OCT)1对阳离子药物的肝脏摄取有贡献。虽然临床证据有限,但临床前研究和建模表明有机阴离子转运体(OAT)2 - 酶在1A类药物清除中存在相互作用。来自试验和临床前模型的数据以及基于生理学的建模方法是理解转运体 - 酶相互作用、预测药代动力学、组织暴露和药物相互作用的关键。当前的方法存在局限性,应着重开发生理学相关模型并表征动物模型,以为机制建模提供信息并提高前瞻性预测的可信度。